{"id":410257,"date":"2021-01-07T08:03:16","date_gmt":"2021-01-07T13:03:16","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=410257"},"modified":"2021-01-07T08:03:16","modified_gmt":"2021-01-07T13:03:16","slug":"entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\/","title":{"rendered":"Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference"},"content":{"rendered":"
\n

WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021.<\/p>\n

The Company\u2019s presentation will be available on demand starting Monday, January 11th<\/sup>, 2021 at 6:00 AM ET, to those attending the conference virtually.<\/p>\n

\n About Entasis<\/strong>
\n
Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis\u2019 pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). For more information, visit www.entasistx.com.<\/p>\n

\n Entasis Company Contact<\/strong>
\n
Kyle Dow
Entasis Therapeutics
(781) 810-0114
kyle.dow@entasistx.com<\/p>\n

\n Investor Relations Contact<\/strong>
\n
James Salierno
The Ruth Group
(646) 536-7028
jsalierno@theruthgroup.com<\/p>\n

\n Media Contact<\/strong>
\n
Annika Parrish
The Ruth Group
(720) 412-9042
aparrish@theruthgroup.com<\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021. The Company\u2019s presentation will be available on demand starting Monday, January 11th, 2021 at 6:00 AM ET, to those attending the conference virtually. About Entasis Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis\u2019 pathogen-targeted design platform has produced a pipeline of product candidates, including … <\/p>\n

Continue reading “Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-410257","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nEntasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021. The Company\u2019s presentation will be available on demand starting Monday, January 11th, 2021 at 6:00 AM ET, to those attending the conference virtually. About Entasis Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis\u2019 pathogen-targeted design platform has produced a pipeline of product candidates, including … Continue reading "Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-07T13:03:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTgyNSMzOTA3OTAzIzIwOTU4NTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference\",\"datePublished\":\"2021-01-07T13:03:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\\\/\"},\"wordCount\":186,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTgyNSMzOTA3OTAzIzIwOTU4NTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\\\/\",\"name\":\"Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTgyNSMzOTA3OTAzIzIwOTU4NTM=\",\"datePublished\":\"2021-01-07T13:03:16+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTgyNSMzOTA3OTAzIzIwOTU4NTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTgyNSMzOTA3OTAzIzIwOTU4NTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\/","og_locale":"en_US","og_type":"article","og_title":"Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference - Market Newsdesk","og_description":"WALTHAM, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) — Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, today announced that Dr. Manos Perros, President and Chief Executive Officer of the Company, will present at the virtual H.C. Wainwright BioConnect 2021 Conference being held January 11-14, 2021. The Company\u2019s presentation will be available on demand starting Monday, January 11th, 2021 at 6:00 AM ET, to those attending the conference virtually. About Entasis Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis\u2019 pathogen-targeted design platform has produced a pipeline of product candidates, including … Continue reading \"Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-07T13:03:16+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTgyNSMzOTA3OTAzIzIwOTU4NTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference","datePublished":"2021-01-07T13:03:16+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\/"},"wordCount":186,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTgyNSMzOTA3OTAzIzIwOTU4NTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\/","name":"Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTgyNSMzOTA3OTAzIzIwOTU4NTM=","datePublished":"2021-01-07T13:03:16+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTgyNSMzOTA3OTAzIzIwOTU4NTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTgyNSMzOTA3OTAzIzIwOTU4NTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/entasis-therapeutics-to-present-at-the-h-c-wainwright-bioconnect-2021-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Entasis Therapeutics to Present at the H.C. Wainwright BioConnect 2021 Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410257","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=410257"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410257\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=410257"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=410257"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=410257"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}